A first-of-its-kind Indian study shows GLP-1 drugs semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro) deliver meaningful weight loss, with tirzepatide outperforming. Patients lost a median 8.2% body weight, 41.3% achieving 10% loss in about nine months. Non-diabetic, younger, and drug-naive patients responded faster. Generics of semaglutide are now widely available.